Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
I-125-OI5V (also known as 125I-OI5V or 125I-2-[4-(2-iodophenyl)piperidino]cyclopentanol) is a radiolabeled vesamicol analog with a five-membered ring structure that acts as a highly selective imaging probe for the sigma-1 receptor (σ1R). Developed by researchers at Kanazawa University, this single-photon emission computed tomography (SPECT) tracer is designed to non-invasively map and monitor the spatiotemporal expression of σ1R, which is upregulated in response to cellular stress such as myocardial ischemia and reperfusion injury, as well as doxorubicin-induced cardiotoxicity. By binding selectively to σ1R, I-125-OI5V serves as a valuable diagnostic tool in preclinical research to evaluate the severity of ischemic burden and assess myocardial viability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on I-125-OI5V.